-
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:15-9. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH.
Obstet Gynecol 2008;31:147-52. -
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2008;28:7-10. -
Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
Spencer K, Kagan KO, Nicolaides KH.
Prenat Diagn 2008;28:49-52. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:488-92. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:493-50. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
Bersinger NA, Noble P, Nicolaides KH.
Prenat Diagn 2003;23:157-62. -
First trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
Spencer K, Noble P, Snijders RJ, Nicolaides KH.
Prenat Diagn 1997;17:525-38. -
Maternal serum concentrations of pregnancy associated plasma protein A and pregnancy specific B-1 glycoprotein in multifetal pregnancies before and after fetal reduction.
Abbas A, Sebire NJ, Johnson M, Bersinger N, Nicolaides KH.
Hum Reprod 1996;11,900-2.